Hodgkin Lymphoma: An Update

Journal for Nurse Practitioners

Volumn 3, Issue 6, 2007, Pages 393-403

  Mullen, Ellen ^a   Zhong, Yazhen ^a  

^a NONE

Author keywords

B symptoms; Hodgkin lymphoma; lymphocytes and histiocytes; novel targeted therapy; Reed Sternberg cells

Indexed keywords

EID: 34249659977     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2007.04.006     Document Type: Article

References (48)

1. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 26 (1966) 1189-1200
2. American Cancer Society. Cancer facts and figures 2006. Available at: www.cancer.org Accessed December 3, 2006.
3. Surveillance Epidemiology End Results (SEER). Cancer stat fact sheets: Hodgkin's lymphoma. Available at: seer.cancer.gov/statfacts. Accessed December 3, 2006.
4. Rosdahl N., Larson S., and Clemmesen J. Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience. Br Med J 2 5913 (1974) 253-256
5. Hjalgrim H., Askling J., Sorensen P., et al. Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 92 18 (2000) 1522-1528
6. Weiss L., Movahed L., Warnke R., et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320 8 (1989) 502-506
7. Pallesen G., Hamilton-Dutoit S., Rowe M., et al. Expression of Epstein-Barr virus latent gene products in tumor cells in Hodgkin's disease. Lancet 337 8737 (1991) 320-322
8. Jarrett R. Viruses and Hodgkin's lymphoma. Ann Oncol 13 S1 (2002) 23-29
9. Jarrett R., Armstrong A., and Alexander E. Epidemiology of EBV Hodgkin's lymphoma. Ann Oncol 7 suppl (1996) S5-S10
10. Goedert J., Cote T., Virgo P., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 9119 (1998) 1833-1839
11. Franceschi S., Dal Maso L., and La Vecchia C. Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer 83 4 (1999) 481-485
12. Grulich A., Wan X., Law M., Coates M., and Kaldor J. Risk of cancer in people with AIDS. AIDS 13 7 (1999) 839-843
13. Clifford G., Polesel J., Rickenbach M., et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97 6 (2005) 425-432
14. Cheung M., Pantanowitz L., and Dezube B. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncology 10 6 (2005) 412-426
15. Engels E., Pfeiffer R., Goedert J., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 12 (2006) 1645-1654
16. Benharroch D., Shemer-Avni Y., Myint Y., et al. Measles virus: evidence of an association with Hodgkin's disease. Br J Cancer 91 3 (2004) 572-579
17. Gutensohn N., and Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 304 3 (1981) 135-140
18. Alexander F., Rickette T., McKinney P., and Cartwright R. Community life style characteristics and incidence of Hodgkin's disease in young people. Int J Cancer 48 1 (1991) 10-14
19. Chang E., Zheng T., Weir E., et al. Childhood social environment and Hodgkin's lymphoma: new findings from a population based case control study. Cancer Epidemiol Biomarkers Prev 13 8 (2004) 1361-1370
20. Landgren O., Engels E., Pfeiffer R., et al. Autoimmunity and susceptibility to Hodgkin's lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 98 18 (2006) 1321-1330
21. Ishibe N., and Tucker M. Epidemiology of Hodgkin's and non-Hodgkin's lymphomas. In: Canettos G., Lister T., and Young B. (Eds). The lymphomas. 2nd ed. (2006), Saunders Elsevier, Philadelphia, PA 127
22. Cozen W., Gill P., Ingles S., et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin's lymphoma. Blood 103 8 (2004) 3216-3221
23. Thomas R., Re D., Wolf J., et al. Part I: Hodgkin's lymphoma-molecular biology of Hodgkin's and Reed-Sternberg cell. Lancet Oncol 5 1 (2004) 11-18
24. Brauninger A., Schmitz R., Bechtel D., et al. Mini review: molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 118 8 (2005) 1853-1861
25. Weinshel E., and Peterson B. Hodgkin's disease. CA: Cancer J Clin 43 6 (1993) 327-372
26. Baetz T., Belch A., Couban A., et al. Gemcitabine, dexamethasone, and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14 12 (2003) 1762-1767
27. Re D., Kuppers R., and Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 23 26 (2005) 6379-6386
28. Mathas S., Lietz A., Anagnostopoulos I., et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199 8 (2004) 1041-1052
29. Khan G. Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma?. Exp Hematol 34 4 (2006) 399-406
30. Marafioti et al.
31. Harris N., Jaffe E., Stein H., et al. A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 84 5 (1994) 1361-1392
32. Feldman A., Pittaluga S., and Jaffe E. Classification and histopathology of the lymphomas. In: Canellos G., Lister T., and Young B. (Eds). The lymphomas. 2nd ed. (2006), Saunders Elsevier, Philadelphia, PA 2
33. Lister T., Crowther D., Sutcliffe S., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 11 (1989) 1630-1636
34. Yahalom J., and Straus D. Hodgkin's lymphoma. In: Pazdur R., Coia L., Hoskins W., and Wagman L. (Eds). Cancer management: a multidisciplinary approach. 9th ed. (2005), CMP Healthcare Media, Lawrence, KS 675
35. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 21 (1998) 1506-1514
36. Van Spronsen D., and Veldhuis G. New development in staging and follow-up of patients with Hodgkin's lymphoma. Neth J Med 61 9 (2003) 278-283
37. Ekstrand B., and Horning S. Hodgkin's disease. Blood Rev 16 2 (2002) 111-117
38. Meyer R., Ambinder R., and Stroobants S. Hodgkin's lymphoma: evolving concepts with implications for practice. Hematology Am Soc Hematol Educ Program (2004) 184-202
39. Hutchings M., Loft A., Hansen M., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin's lymphoma. Blood 107 1 (2006) 52-59
40. Rueda A., Olmos D., Viciana R., et al. Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment. Clin Lymphoma Myeloma 6 5 (2006) 389-393
41. NCCN Clinical Practice Guidelines in Oncology V. 1. (2006). Hodgkin's Disease/Lymphoma.
42. Yazbeck V., Georgakis G., Wedgwood A., et al. Hodgkin's lymphoma: molecular targets and novel treatment strategies. Future Med 2 4 (2006) 533-551
43. Zinzani P., Magagnoli M., Frezza G., et al. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease. Leuk Lymphoma 32 5-6 (1999) 553-559
44. Zheng B., Georgakis G., Li Y., et al. Introduction of cell-cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin's disease cell lines is independent of inhibitor of NF-kB mutations or activations of CD30, CD40 and RANK receptors. Clin Cancer Res 10 9 (2004) 3207-3215
45. Younes A., Pro B., and Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin's lymphoma [letter]. Blood 107 4 (2006) 1731a-1732a
46. Takayama S., Reed J., and Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 22 56 (2003) 9041-9047
47. Georgakis G., and Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol 1 2 (2005) 273-281
48. Vose J., Constine L., and Sutcliffe S. Other complications of the treatment of Hodgkin's disease. In: Mauch P., Armitage J., and Diehl V. (Eds). Hodgkin's disease (1999), Lippincott Williams and Wilkins, London, United Kingdom 661-671